Protective Effects of Caffeine on Chronic Hypoxia-induced Perinatal White Matter Injury
Overview
Authors
Affiliations
Objective: Periventricular white matter injury (PWMI) is the major cause of cerebral palsy and cognitive impairment in prematurely born infants. PWMI is characterized by reductions in cerebral myelination and cerebrocortical volumes and is associated with secondary ventriculomegaly. In neonatal rodents, these features of PWMI can be induced by rearing in chronic hypoxia or by activation of A1 adenosine receptors. We determined: (1) whether altered maturation or development of one or more oligodendrocyte (OL) lineage stages plays a role in the pathogenesis of the myelination disturbances associated with exposure to chronic hypoxia, and (2) whether blockade of A1 adenosine receptor action with the adenosine antagonist caffeine can prevent hypoxia-induced white matter injury.
Methods: Ventriculomegaly and reduced cerebral myelination were generated in mice reared in hypoxia (10% oxygen) from postnatal days 3 (P3) through 12.
Results: Hypomyelination was related to abnormal OL lineage progression and a reduction in the OL progenitor pool. Myelination was enhanced and ventriculomegaly reduced in hypoxia-exposed neonatal pups treated with caffeine from P3 to P12.
Interpretation: These observations support that hypoxia inhibits OL maturation and that caffeine administration during early postnatal development may have utility in the prevention of PWMI.
Bernis M, Burkard H, Bremer A, Grzelak K, Zweyer M, Maes E Int J Biol Sci. 2025; 21(1):251-270.
PMID: 39744433 PMC: 11667826. DOI: 10.7150/ijbs.101087.
Endesfelder S Antioxidants (Basel). 2024; 13(9).
PMID: 39334735 PMC: 11429035. DOI: 10.3390/antiox13091076.
Minimum effective dose of clemastine in a mouse model of preterm white matter injury.
Odell E, Jabassini N, Schniedewind B, Pease-Raissi S, Frymoyer A, Christians U Pediatr Res. 2024; 96(4):933-941.
PMID: 38942888 PMC: 11502491. DOI: 10.1038/s41390-024-03326-w.
Molloy E, El-Dib M, Soul J, Juul S, Gunn A, Bender M Pediatr Res. 2023; 95(5):1224-1236.
PMID: 38114609 PMC: 11035150. DOI: 10.1038/s41390-023-02895-6.
A phase I trial of caffeine to evaluate safety in infants with hypoxic-ischemic encephalopathy.
Jackson W, Gonzalez D, Greenberg R, Lee Y, Laughon M J Perinatol. 2023; 44(4):508-512.
PMID: 37587184 PMC: 10869636. DOI: 10.1038/s41372-023-01752-y.